Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development - Transpla...
January 29 2021 - 9:24AM
via NewMediaWire-- Aditx Therapeutics, Inc. (Aditxt)
(the “Company”) (Nasdaq: ADTX), a biotech innovation company
developing biotechnologies specifically focused on improving the
health of the immune system through immune monitoring and
reprogramming, today announced the appointment of Dr. Dolly B. Tyan
as Senior Vice President of Clinical Development – Transplantation.
In this role, Dr. Tyan will be overseeing Aditxt’s therapeutic
program for organ rejection including advancing current candidates
towards clinical trials and developing new products for new
applications.
Dr. Tyan’s career of over 45 years prior to
joining Aditxt was devoted to nine solid organ and two bone
marrow/stem cell transplant programs for both adult and pediatric
patients. She is the inventor of four novel and now patented
technologies that have transformed transplantation therapeutics and
technology worldwide. The major thrust of Dr. Tyan’s career has
been aimed at more accurately and clearly defining the
immunological state of the transplant candidate/recipient and
monitoring their immune response over time with novel technologies.
She has developed new clinical tests to replace the ones in
standard use for the last 30-50 years and developed a therapeutic
strategy for altering the immune status of a patient to improve
their chance of receiving a transplant and long-term acceptance of
even an incompatible organ. Key to this is understanding the
patient’s immune profile in real time.
Dr. Tyan will begin her work at Aditxt by
advancing the Company’s proprietary technology, Apoptotic DNA
Immunotherapy™ (ADi™), which is designed to retrain the immune
system to induce tolerance, in the field of organ transplantation.
The initial focus is on skin allografts. In this role she will join
Dr. Friedrich Kapp, MD, PhD, who is leading Aditxt’s Autoimmunity
therapeutic program, to guide the clinical advancement of the
therapeutic division of the Company.
Amro Albanna, Co-Founder and CEO of Aditxt,
commented, “Dr. Tyan will help drive our mission in the important
area of immune reprogramming, one of our two core segments –
AditxtReprogramming™ and AditxtScore™. She is an Immunologist and
Clinical Transplant expert who has spent much of her career working
alongside transplant surgeons, acquiring an intimate knowledge and
understanding of innovative approaches that are needed to increase
organ acceptance. With Dr. Tyan now on board, and together with Dr.
Kapp, they will drive AditxtReprogramming™ activities as we
work toward the commencement of Phase l/lla clinical trials.”
Dr. Tyan added, “My interest in joining Aditxt is
our shared ambition to reach the ultimate goal of transplantation,
which is to induce tolerance, where one transplanted organ lasts a
lifetime without immunosuppression, as if it were the patient’s
own. The Aditxt approach not only holds the promise of a
breakthrough in this longstanding, intractable clinical problem,
but if further advanced could solve another enormous worldwide
problem. There are not enough donor organs for all those who need
them; the donation rates are steady, but the need continues to grow
annually. Part of the reason for this is that transplanted patients
often lose their organs due to incompatibility and drug toxicity as
well as the inability of immunosuppressive drugs to maintain
control over the long term without themselves injuring the organs,
leading to chronic rejection. These patients, if otherwise
qualified after losing an organ, come back onto the waiting list,
thus adding to the burgeoning numbers of waitlisted patients. I
believe that the Aditxt approach can lead to One Organ for
Life and this is what draws me to commit my time and
experience into making this happen.”
Dolly B. Tyan, PhD, D(ABHI) obtained her PhD in
Microbiology & Immunology from the University of California,
Los Angeles, became a faculty member there in Pediatrics with an
emphasis in Genetics, and was the Clinical Director of the
Histocompatibility and Immunogenetics Laboratory at Cedars-Sinai
Medical Center in Los Angeles for 19 years. She was a key faculty
member in the immunogenetics of autoimmune disease including Type 1
diabetes and Inflammatory Bowel Disease profiling. Prior to this
she led the Histocompatibility Lab at Stanford University for 15
years. She was recruited back to Stanford as Professor of Pathology
and Medical Director of the Histocompatibility, Immunogenetics
& Disease Profiling Laboratory in 2006, retiring in 2019. She
was also the Director of Education & Innovation.
Dr. Tyan has also been very active on the national
stage. She was Vice President, President, and Immediate Past
President of the American Society for Histocompatibility &
Immunogenetics in 2000-2002. From 2000-2016, she served on multiple
committees in the United Network for Organ Sharing, the U.S.
Government’s contract organization responsible for all solid organ
transplant allocation in the U.S. She served on the Executive
Board, was Chair of the Histocompatibility Committee, and was a
member of the Kidney/ Pancreas, Kidney, Operations, Strategic
Planning, Policy Oversight, Quality Assurance and Standards, and
Membership and Professional Standards committees.
She also served on the Histocompatibility
Committee of the National Marrow Donor Program. On a more regional
level, she was on the Medical Advisory Board and the Executive
Board of the California Transplant Donor Network (later Donor
Network West), the organ procurement organization responsible for
solid organ allocation in northern and central California from
2008-2019.
AditxtReprogramming™ Immune Reprogramming
Technology
Aditxt is commercializing a nucleic acid-based
technology named Apoptotic DNA Immunotherapy™ (ADi™) which utilizes
a novel approach that mimics the way the body naturally induces
tolerance to our own tissues (therapeutically induced immune
tolerance). ADi™ is a technology platform which we believe can be
engineered to address a wide variety of indications.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated September 1, 2020, that was filed with the
Securities and Exchange Commission under File No. 333-248491, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Contacts:
Investor RelationsJeff Ramson
PCG Advisory
Chief Executive Officer
IR@aditxt.com
646-863-6341
Public Relations
Kevin Harrington
5W Public Relations
aditxt@5wpr.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024